



**HANNA KELLY SANOFF, M.D.**  
**CURRICULUM VITAE**

- Section Chief of Gastrointestinal Medical Oncology, Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC 6/2013 – present
- Assistant Professor, Department of Medicine, Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC 1/2013 – 10/2015
- Medical Director, UVA Medical Oncology Clinical Trials Office, 10/2010 – 8/2012
- Assistant Professor, Department of Medicine, Division of Hematology-Oncology, University of Virginia, Charlottesville, VA 9/2009 – 8/2012
- Clinical Assistant Professor, Division of Hematology-Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 9/2009 – 8/2012
- Assistant Professor, Department of Medicine, Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC 7/2006 – 7/2009

**4) Honors and Awards**

- Recognition, UpToDate Best Authors in Oncology, 2017.
- UNC Health Care and Faculty Physicians Carolina Care Excellence Leader, 2016, 2017
- Best Doctors in America<sup>®</sup>, 2013- 2017
- University of Virginia Department of Medicine Award for Outstanding Young Investigator, 2012
- American Cancer Society Institutional Research Grant (UVA), 2010
- UVA Cancer Center Commonwealth Fund for Cancer Research, Pilot award, 2010
- America's Top Doctors, Castle Connolly/US News & World Report, 2010
- UNC Medical Foundation Excellence Fund, Seed Grant, 2007
- NIH Loan Repayment Program, 2006, 2008
- Lineberger Cancer Center Population Sciences Developmental Award, 2006
- Selected for the AACR “*Molecular Biology in Clinical Oncology*” workshop, 2005
- Amgen Hematology-Oncology Fellowship Award, 2005
- The Chairman's Award, UNC Department of Medicine, 2003
- The Golden Boots Award, UNC Department of Medicine resident award, 2002
- David A. Ontjes Award, UNC Department of Medicine intern award, 2001

**5) Bibliography**

**Books and chapters**

1. Ramsdale E, **Sanoff H**, Muss, H. Approach to the older patient with stage II/III colorectal cancer: who should get curative-intent therapy? In: Am Soc Clin Oncol Educ Book 2013: 163-168. asco.org/edbook. PMID 23714489.
2. **Sanoff HK** and Schrag D. Outcomes Research in Colorectal Cancer. In: Kelsen DP, Daly JM, Kern SE, Levin B, Tepper JE, Van Cutsem E (eds). *Gastrointestinal Oncology, Principles and Practice, second edition*. Philadelphia, PA: Lippincott, Williams & Wilkins, 2008: 127-134.

**HANNA KELLY SANOFF, M.D.**  
**CURRICULUM VITAE**

3. **Sanoff HK** and Mitchell B. Leukemias. In: Runge MS and Greganti MA (eds). *Netter's Internal Medicine, second edition*. Philadelphia, PA. Elsevier; 2008: 536-540.
4. O'Neil BH, **Kelly H**, Morse MA, Goldberg RM. Adjuvant chemotherapy for colon cancer. In: Saltz LB ed. *Colorectal Cancer. Evidence-based chemotherapy strategies*. Totowa, New Jersey: Humana Press; 2007: 131-154.
5. **Kelly H**, Collichio F, Dees EC. Concomitant Pregnancy and Breast Cancer: Options for Systemic Therapy. In: Breast Disease, Vol. 23. IOS Press 2006, pgs. 95-101.
6. **Kelly H** and Goldberg RM. Clinical Trials and Emerging Therapies. In: *The American Cancer Society's Complete Guide to Colorectal Cancer*. Atlanta, Georgia: The American Cancer Society; 2006: 209-220.
7. **Kelly H** and Socinski MA. Cardiac Tumors. In: Runge MS, Ohman EM, ed. *Netter's Cardiology*. Teterboro, New Jersey: Icon Learning Systems; 2004: 554-561.

Refereed papers/articles

*Original research (trainees are underlined)*

1. **Sanoff HK**, Chang YK, Lund JL, O'Neil BH, Dusetzina SB. Immortal time bias or sorafenib effect in elderly patients with HCC? [Letter to the editor] *Hepatology* 2017; 66(2): 678-679 PMIDL 28510340
2. Guerard EJ, Deal AM, Chang YK, Williams GR, Nyrop KA, Pergolotti M, Muss HB, **Sanoff HK**, Lund JL. Frailty indexed developed from a cancer-specific geriatric assessment and the association with mortality among older adults with cancer. *J Natl Compr Canc Netw* 2017; 15(7): 894-902. PMID: 28687577
3. Lund JL, Deal A, Chang YK, Meyer AM, Choi BJ, Muss H, **Sanoff HK**. Data Linkage to Improve Geriatric Oncology Research: A feasibility study. *The Oncologist*, 2017, April 12 [epub] PMID: 28408619
4. **Sanoff HK**. Targeting HER2 Beyond Progression in Gastroesophageal Cancer. *Lancet Oncology*, 2017; March 23 [epub]. PMID: 28343978. [Invited Commentary].
5. Murphy CC, **Sanoff HK**, Stitzenberg KB, Baron JA, Sandler RS. Patterns of sociodemographic and clinicopathologic characteristics of stages II and III colorectal cancer patients by age: Examining potential mechanisms of young-onset disease. *Journal of Cancer Epidemiology* 2017; Jan 23 [epub] PMID: 28239395
6. Reeve BB, Thissen DM, Bann CM, Mack N, Treiman K, **Sanoff HK**, Roach N, Magnus BE, He J, Wagner LK, Moultrie R, Jackson KD, Mann C, McCormack LA. Psychometric evaluation and design of patient-centered communication measures for cancer care settings. *Patient Education and Counseling* 2017; Feb 10 [epub] PMID 28214167
7. Williams GR, Deal AM, Muss HB, Weinberg MS, **Sanoff HK**, Guerard EJ, Nyrop KA, Shachar SS. Skeletal muscle measures and physical function in older adults with cancer: sarcopenia or myopenia? *Oncotarget* 2017; 4 April [epub] PMID: 28431396
8. **Sanoff HK**, Chang YK, Reimers M, Lund JL. Hospice utilization and its effect on acute care needs at the end of life in Medicare beneficiaries with hepatocellular carcinoma. *J Oncol Practice*, 2016 Dec 28 [epub] PMID: 28029300

**HANNA KELLY SANOFF, M.D.**  
**CURRICULUM VITAE**

- **Sanoff HK**, Chang Y, Reimers M, Lund J. Reply to CD Woodrell et al. *J Oncol Pract* 2017; 13 (6): 406 PMIDL 28504902
- 9. Ellis CT, Dusetzina SB, **Sanoff HK**, Stitzenberg KB. Long-term survival after chemoradiotherapy without surgery for rectal adenocarcinoma: A word of caution. *JAMA Oncology*, 2016, Oct 20 [epub ahead of print] PMID: 27768159
  - Ellis CT, **Sanoff HK**, Stitzenberg KB. Inferior survival rates after chemoradiation for rectal cancer without surgery-Reply. *JAMA Oncol* 2017, April. PMID: 28448650 [Reply to letter to the editor]
- 10. Treiman K, McCormack L, Olmsted M, Roach N, Reeve B, Martens CE, Moultrie R, **Sanoff H**. Engaging patient advocates and other stakeholders to design measures of patient-centered communication in cancer care. *Patient*, 2016; Sept 23 [epub] PMID 27658673
- 11. Murphy CC, Sandler RS, **Sanoff HK**, Yang YC, Lund JL, Baron JA. Decrease in incidence of colorectal cancer among individuals 50 years or older following recommendations for population-based screening. *Clin Gastroenterol Hepatol*; 2016, Sept 5 [Epub ahead of print] PMID: 27609707
- 12. **Sanoff HK**, Chang YK, Lund JL, O'Neil BH, Dusetzina S. Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. *The Oncologist* 2016; 21 (9): 1113-20. PMID: 27185615.
- 13. Lund JL, Stürmer T, **Sanoff HK**. Comparative effectiveness of postoperative chemotherapy among non-metastatic rectal cancer patients treated with preoperative chemoradiotherapy. *J Geriatr Oncol* 2016; 7(3): 176-86. PMID: 26926829.
- 14. McRee AJ, **Sanoff HK**, Carlson C, Ivanova A, O'Neil BH. A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. *Investigational New Drugs* 2015; 33 (6); 1225-31. PMID 26490655.
- 15. Broughman JR, Williams GR, Deal AM, Yu H, Nyrop KA, Alston SM, Gordon BB, **Sanoff HK**, Muss HB. Prevalence of sarcopenia in older patients with colorectal cancer. *J Geriatr Oncol*. 2015 6(6): 442-5. PMID: 26365898.
- 16. **Sanoff HK**, Chang Y, Stavas JM, Stürmer T, Lund J. Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries. *J Natl Compr Canc Netw*. 2015 Sep;13(9):1102-10. PMID: 26358794.
- 17. **Sanoff HK**, Morris WL, Mitcheltree AL, Wilson S, Lund JL. Lack of support and information regarding long-term negative effects in survivors of rectal cancer. *Clin J Oncol Nurs*, 2015; 19 (4): 444-448. PMID: 26207709.
- 18. Williams GR, Nyrop K, Deal A, Muss H, **Sanoff HK**. Self-directed Physical Activity Intervention in Older Adults Undergoing Adjuvant Chemotherapy for Colorectal Cancer: Design of a Randomized Controlled Trial. *Contemporary Clinical Trials* 2015; 42: 90-97. PMID: 25827253.
- 19. **Sanoff HK**, Kim R, Ivanova A, Alistar A, McRee AJ, O'Neil BH. Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma. *Invest New Drugs*, 2015; 33(2): 505-9. PMID: 25613083.
- 20. Williams GR and **Sanoff HK**. Adjuvant chemotherapy in older adults with colon cancer. *American Journal of Hematology/Oncology*, 2015; 11 (3): 5-10.

**HANNA KELLY SANOFF, M.D.**

**CURRICULUM VITAE**

21. Quach C, **Sanoff HK**, Williams GR, Lyons JC, Reeve BB. Impact of colorectal cancer diagnosis and treatment on health-related quality of life among older Americans: A population-based, case-control study. *Cancer*, 2014. [Epub ahead of print] PMID: 25377096.
22. Penn DC, Chang YK, Meyer AM, Mack CD, **Sanoff HK**, Stitzenberg K, Carpenter, WR. Provider-based research networks may improve early access to innovative colon cancer treatment for African Americans. *Cancer*, 2015; 121 (1): 93-101. PMID 25209056.
23. McRee, AJ, Davies JM, **Sanoff H**, Goldberg RM, Bernard S, Dees EC, Keller K, Ivanova A, O'Neil BH. A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. *Cancer Chemother Pharmacol*. 2014; 74 (1): 117-123. PMID 24819684.
24. Sorrentino JA, **Sanoff HK**, Sharpless NE. Defining the toxicology of aging. *Trends in Molecular Medicine*. 2014; 20 (7): 375-384 PMID 24880613.
25. **Sanoff HK**, Deal A, Krishnamurthy J, Torrice C, Dillon P, Sorrentino J, Ibrahim JG, Jolly T, Williams G, Carey LA, Drobish A, Gordon B, Alston S, Hurria A, Rudolph KL, Sharpless NE, Muss HB. Effect of Cytotoxic Chemotherapy on Markers of Molecular Age in Patients with Breast Cancer. *JNCI* 2014 Apr, 106(4): dju057. PMID: 24681605.
26. Cosgrove ND, Al-Osaimi AM, **Sanoff HK**, Morris MM, Read PW, Cox DG, Mann JA, Argo CK, Berg CL, Pelletier SJ, Maluf DG, Wang AY. Photodynamic therapy provides local control of cholangiocarcinoma in patients awaiting liver transplantation. *Am J of Transplant*, 2014; 14(2): 466-71. PMID 24373228.
27. Chakraborty S, Morris MM, Bauer TW, Adams RA, Stelow EB, Petroni G, **Sanoff HK**. Accelerated fraction radiotherapy with capecitabine as neoadjuvant therapy for borderline resectable pancreatic cancer. *Gastrointestinal Cancer Research* 2014; 7(1): 15-22. PMID: 24558510.
28. **Sanoff HK**, Renfro L, Poonnen P, Sargent DJ, Goldberg RM, McLeod H. Germline variation at colorectal cancer risk loci does not influence treatment effect or survival in metastatic colorectal cancer. *PLoS One* 2014; 9(4): e94727 PMID: 24727911.
29. Stitzenberg KB, **Sanoff HK**, Penn DC, Meyers MO, Tepper JE. Practice patterns and long-term survival for early stage rectal cancer. *J Clin Oncol* 2013; 31(34): 4276-82. PMID 24166526.
30. **Sanoff HK** and Goldberg RM. How we treat metastatic colon cancer in older adults. *Journal of Geriatric Oncology*, 2013; 4(4): 295-301. PMID: 24472471.
31. Lund JL, Stürmer T, **Sanoff HK**, Brookhart A, Sandler RS, Warren J. Determinants of oxaliplatin receipt among older stage II and III colon cancer patients. *Cancer*, 2013. Jun 1; 119(11): 2038-47. PMID 23512326.
32. Lund JL, Stürmer T, Harlan LC, **Sanoff HK**, Sandler RS, Brookhart MA, Warren JL. Identifying specific chemotherapeutic agents in Medicare data: a validation study. *Med Care*. 2013 May; 51(5): e27-34. PMID: 22080337.
33. **Sanoff HK**, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, Goldberg RM, Schymura MJ, Schrag D. Comparison of adverse events during 5FU versus 5FU/oxaliplatin adjuvant chemotherapy for stage III colon cancer: A population based analysis. *Cancer*, 2012; 118(17): 4309-20. PMID 22294436.

**HANNA KELLY SANOFF, M.D.**  
**CURRICULUM VITAE**

34. Carpenter WR, Meyer AM, Wu Y, Qaqish B, **Sanoff HK**, Goldberg RM, Weiner BJ. Translating research into practice: the role of provider based research networks in the diffusion of an evidence-based colon cancer treatment innovation. *Medical Care* 2012, 50(8): 737-48. PMID 22437624.
35. **Sanoff HK**, Carpenter WR, Sturmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, Schrag D. The effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75. *J Clin Oncol*, 2012; 30(21): 2624-2634. PMID 22665536.
  - **Sanoff HK**, Carpenter WR, Stürmer T. *J Clin Oncol* 2013; 31 (4): 512-3. [in response to comment on Sanoff HK, et al. The effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75. *J Clin Oncol*, 2012; 30(21): 2624-2634. PMID 23472263.
36. Mack CD, Carpenter WR, Meyer AM, **Sanoff HK**, Stürmer T. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer. *Cancer*, 2012; 118(11): 2925-34. PMID 22072441.
37. Meyerhardt JA, Li L, **Sanoff HK**, Carpenter WR, Schrag D. Effectiveness of bevacizumab with first-line combination chemotherapy for medicare patients with stage IV colorectal cancer. *J Clin Oncol*, 2012; 30(6): 608-15. PMID 22253466.
38. **Sanoff HK**, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Stürmer, T, Fine JP, Weeks J, Niland J, Kahn KL, Schymura MJ, Schrag, D. Comparative effectiveness of oxaliplatin-containing versus non-oxaliplatin adjuvant chemotherapy for stage III colon cancer. *J Natl Cancer Inst*, 2012; 104(3): 211-27. PMID 22266473.
39. **Sanoff HK**, Davies JM, Walko C, Irvin W, Buie L, Keller K, Ivanova A, Chiu WK, O'Neil BH, Stinchcombe TE, Dees EC. A Phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors. *Investigational New Drugs*, 2011; 29(5): 978-83. PMID 20387090.
40. **Sanoff HK**, Bernard S, Goldberg RM, Morse MA, Garcia R, Woods L, Moore DT, O'Neil BH. Phase II study of capecitabine, oxaliplatin, cetuximab for advanced hepatocellular carcinoma. *Gastrointestinal Cancer Research* 2011; 4(3): 78-83. PMID 22043322.
41. **Sanoff HK**, Davies J, Walko C, Buie L, Chiu WK, Ivanova A, O'Neil B, Stinchcombe TE, Keller K, Dees EC. Phase I trial of vinflunine and pemetrexed in refractory solid tumors. *Invest New Drugs*. 2011; 29(1): 131-136. PMID19830387.
42. Burd CE, Jeck WR, Liu Y, Sanoff HK, Wang Z, Sharpless NE. Expression of linear and novel circular forms of INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. *PLoS Genet* 2010; 6(12): e10001233. PMID 21151960.
43. Song Z, von Figura G, Liu Y, Kraus JM, Torrice C, Dillon P, Rudolph-Watabe M, Ju Z, Kestler HA, **Sanoff H**, Rudolph KL, Lifestyle impacts on the aging-associated expression of biomarkers of DNA damage and telomere dysfunction in human blood. *Aging Cell*, 2010; 9(4): 607-15. PMID 20560902.
44. **Sanoff HK**, Goldberg RM, Pignone MP. Assessing the quality of initial consultations regarding adjuvant colon cancer therapy. *Clin Colorectal Cancer*, 2010; 9(2): 113-118. PMID 20378506.

## HANNA KELLY SANOFF, M.D.

### CURRICULUM VITAE

45. O'Neil BH, Raftery L, Calvo BF, Chakravarthy AB, Ivanova A, Meyers MO, Kim HJ, Chan E, Wise PE, Caskey LS, Bernard SA, **Sanoff HK**, Goldberg RM, Tepper JE. A phase I study of bortezomib in combination with standard 5-fluorouracil and external beam radiotherapy for the treatment of locally advanced or metastatic rectal cancer. *Clin Colorectal Cancer* 2010; 9(2): 119-125. PMID 20378507.
46. Goldberg RM, Sargent DJ, Morton RF, Green E, **Sanoff HK**, McLeod H, Buckner J. NCCTG study N9741: Leveraging learning from an NCI cooperative group phase III trial. *The Oncologist*, 2009; 14(10): 970-978. PMID 19828593.
47. Tsygankov D, Liu Y, **Sanoff H**, Sharpless N, Elston T. A Quantitative Model for Age-Dependent Expression of the p16INK4a Tumor Suppressor. *Proc Natl Acad Sci U S A*. 2009; 29; 106(39): 16562-7. PMID 19805338.
48. **Sanoff HK**, Sargent DJ, Green EM, McLeod HL, Goldberg RM. Racial Differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. *J Clin Oncol*, 2009; 27(25): 4109-15. PMID 19636001.
49. Liu Y, **Sanoff HK**, Cho H, Burd CE, Torrice C, Ibrahim JG, Thomas NE, Sharpless NE. Expression of p16INK4a in peripheral blood T-cells is a biomarker of human aging. *Aging Cell*, 2009, 8(4): 439-48. PMID 19485966.
50. Sargent DJ, Köhne CH, **Sanoff HK**, Bot BM, Seymour MT, de Gramont A, Porschen R, Saltz LB, Rougier P, Tournigand C, Douillard JY, Stephens RJ, Grothey A, Goldberg RM.. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in 9 first line treatment trials using individual patient date from 6,286 patients with metastatic colorectal cancer. *J Clin Oncol*, 2009; 27(12): 1948-55. PMID 19255311.
51. **Sanoff, HK** and O'Neil BH. Adjuvant therapy for colorectal cancer: Increasingly complex as patients age. *Oncology (Williston Park)*; 2009; 23(2): 173-4. PMID 19323299.
52. Liu Y, **Sanoff HK**, Cho H, Burd CE, Torrice C, Mohlke KL, Ibrahim JG, Thomas NE, Sharpless NE. *INK4/ARF* Transcript Expression Is Associated with Chromosome 9p21 Variants Linked to Atherosclerosis. *PLoS ONE* 2009; 4(4): e5027. PMID 19343170.
53. **Sanoff HK**, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM. N9741: 5 Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer. *J Clin Oncol*, 2008; 26(35): 5721-7. PMID 19001325.
54. Raftery L, **Sanoff HK**, Goldberg RM. Colon cancer in older adults. *Seminars in Oncology*, 2008; 35: 561-568. PMID 19027460.
55. **Sanoff HK** and McLeod HL. Predictive factors for response and toxicity in chemotherapy: Pharmacogenomics. *Seminars in Colon and Rectal Surgery*, 2008; 19(4): 226-230. PMID 19956343.
56. **Sanoff HK**, Goldberg RM. Colorectal cancer treatment in older patients. *Gastrointest Cancer Res* 2007; 1(6): 248-253. PMID 19262903.
57. **Sanoff HK**, Goldberg RM, Pignone MP. A systematic review of the use of quality of life measures in colorectal cancer research with attention to outcomes in the elderly. *Clinical Colorectal Cancer*, 2007; 6(10): 700-709. PMID 18039423.

**HANNA KELLY SANOFF, M.D.**

**CURRICULUM VITAE**

58. **Sanoff HK**, Bleiberg H, Goldberg RM. Managing older patients with colorectal cancer. *J Clin Oncol* 2007; 25(14): 1891-1897. PMID 19262903.
59. O'Neil BH, Bůzková P, Farrah H, Kashatus D, **Sanoff H**, Goldberg RM, Baldwin AS, Funkhouser WK. Expression of nuclear factor-kappaB family of proteins in hepatocellular carcinomas. *Oncology* 2007; 72(1-2): 97-104. PMID 18025803.
60. **Kelly H**, Graham M, Humes E, Dorflinger LJ, Boggess KA, O'Neil BH, Harris J, Spector NL, Dees EC. Delivery of a healthy baby after first trimester maternal exposure to the EGFR and HER2 inhibitor lapatinib. *Clinical Breast Cancer* 2006; 7(4): 339-41. PMID 17092403.
61. **Kelly H**, Kimmick G, Dees EC, Collichio F, Gatti L, Sawyer L, Ivanova A, Dressler L, Graham ML, Carey LA. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. *Clin Breast Cancer* 2006; 7: 237-243. PMID 16942640.
62. **Kelly H**, Harvey D, and Moll S. A cautionary tale: Fatal outcome of methotrexate therapy given for management of ectopic pregnancy. *Obstet Gynecol* 2006; 107: 439-441. PMID 16449141.
63. **Kelly H** and O'Neil BH. Response of epithelioid hemangioendothelioma to treatment with liposomal doxorubicin. *Lancet Oncol*, 2005; 6: 813-815. PMID 16198988.
64. **Kelly H** and Goldberg RM. Systemic therapy for metastatic colorectal cancer: Current options, current evidence. *J Clin Oncol* 2005; 23: 4553-4560. PMID 16002847.
65. **Kelly H**, Collichio FA, Dees EC. Concomitant pregnancy and breast cancer—options for systemic therapy. *Breast Dis* 2005-2006; 23: 95-101. PMID 16823172.

*In Press/Submitted manuscripts*

1. Nishijima TF, Kardos J, Chai S, Smith CC, Bortone DS, Selitsky SR, Parker JS, **Sanoff HK**, Lee MS, Vincent BG. Molecular and clinical characterization of a claudin-low subtype of gastric cancer. *JCO Clinical Cancer Informatics*, accepted for publication 5/2017
2. Cole AL, **Sanoff HK**, Dusetzina SB. Trends in capecitabine spending before and after generic market entry among commercially-insured patients. *Submitted to Health Affairs*, 11/2016

*Published abstracts (trainees are underlined)*

1. Nishijima TF, Kardos J, Chai S, Smith CC, Bortone DS, Mose LE, Selitsky SR, **Sanoff HK**, Parker JS, Lee MS, Vincent BG. Molecular and clinical characterization of a claudin (CLDN)-low subtype of gastric cancer. *J Clin Oncol* 2017; 35 (suppl 4): abstract 67
2. Williams GR, Deal A, Shachar SS, Walko C, Patel J, O'Neil B, McLeod HL, Weinberg M, Choi SK, Muss HB, **Sanoff HK**. The Impact of Sarcopenia on Toxicity and Pharmacokinetics of 5-Fluorouracil in Colorectal Cancer. *J Clin Oncol* 35, January 2017: Suppl 4S: abstract 633.
3. Williams GR, Deal A, Muss HM, **Sanoff HK**, Weinberg M, Shachar SS. Computerized Tomography (CT) Assessed Body Composition (BC) and Physical Function in Older Adults with Cancer. *J Clin Oncol*. 2016; Suppl: abstr



**HANNA KELLY SANOFF, M.D.**  
**CURRICULUM VITAE**

4. Lee MS, Vincent BG, McRee AJ, **Sanoff HK**. Association between cetuximab response and differential immunologic gene expression signatures in colorectal cancer metastases. *J Clin Oncol* 2016; 34 (4 suppl): abstract 558
5. Williams GR, Deal A, **Sanoff HK**, Mackenzi P, Nyrop K, Shachar SS, Reeve BB, Guerard EJ, Bensen J, Choi SK, Muss HM. Frailty and Health-Related Quality of Life (HRQOL) in Older Women with Breast Cancer. *J Clin Oncol*. Suppl: abstr 2016.
6. Lund JL, Hinton SP, **Sanoff HK**, Pate V, Jirón M, Burkhart JI, Muss HB, Stürmer T. "Patterns and Predictors of Potentially Inappropriate Medication Use in Older Breast, Colon, and Lung Cancer Patients in the United States" *32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016. Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 374.
7. Williams GR, Deal A, Muss HM, **Sanoff HK**, Weinberg M, Shachar SS. Frailty and Computerized Tomography (CT) Assessed Body Composition in Older Adults with Cancer. *The Journal of Frailty & Aging*. Supplement 1, Vol 5, p 26-27. 2016.
8. Lund JL, Murphy CC, Peacock Hinton S, **Sanoff HK**, Stürmer T. "Evaluating heterogeneity of adjuvant chemotherapy effectiveness among older adults diagnosed with stage III colon cancer" *2016 Epidemiology Congress of the Americas*, Miami, FL June 21-24, 2016
9. Cole AL, **Sanoff HK**, Dusetzina SB. Trends in commercial spending on capecitabine before and after generic product entry. 21<sup>st</sup> Annual Meetings of the International Society for Pharmacoeconomics and Outcomes Research, Washington DC, May 2016.
10. Lund JL, **Sanoff HK**, Stürmer T. "Identifying heterogeneity of comorbid diabetes among older colon cancer patients: A latent class analysis" *15<sup>th</sup> Annual Meeting of the International Society for Geriatric Oncology*, Prague, Czech Republic November 12-14, 2015. Available through *Journal of Geriatric Oncology* 2015; 6(S1): S74.
11. Lund JL, **Sanoff HK**, Stürmer T. "Controlling for markers of frailty in cancer comparative effectiveness research among older adults" *31st International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Boston, MA August 22-26, 2015. Available through *Pharmacoepidemiology and Drug Safety* 2015; 24(S1): 2.
12. Wang A, **Sanoff HK**, McRee AJ, O'Neil BH, Calvo BF, Hennessy MG, Murphy C, Tynan MT, Blackstock AW, Gamey EG, Tepper JE. Phase IB/II study of neoadjuvant chemoradiotherapy with CRLX101 with capecitabine for locally advanced rectal cancer. *J Clin Oncol* 33, 2015 (suppl; abstr TPS3629)
13. Williams GR, Innocenti F, Wood W, Patel J, Sherrill GB, O'Neil BH, Boles J, Basch E, **Sanoff HK**. *Genotype-directed Phase II Study of Irinotecan Dosing in Metastatic Colorectal Cancer (mCRC) Patients Receiving FOLFIRI + Bevacizumab: The GENIC Study*. *J Clin Oncol* 33, 2015 (suppl; abstr TPS3621)
14. Wang A, Tian X, Nguyen M, McRee AJ, **Sanoff HK**, O'Neil BH, Hennessy MG, Eliasof S, Gamey EG, Tepper JE. Improving neoadjuvant chemoradiotherapy for rectal cancer with CRLX101, a nanoparticle-drug conjugate, with a captothecin payload. *J Clin Oncol* 33, 2015 (suppl; abstr 645).
15. Lund JL, Stürmer T, **Sanoff HK**. Comparative effectiveness of contemporary adjuvant chemotherapy among older rectal cancer patients. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 3579).

**HANNA KELLY SANOFF, M.D.**

**CURRICULUM VITAE**

16. **Sanoff HK**, Chang YK, Lund JL, Stürmer T. Initial therapy with transarterial chemoembolization versus Yttrium<sup>90</sup> radioembolization for hepatocellular carcinoma. Clin Oncol 32, 2014 (suppl; abstr e15131).
17. Elban MJ, **Sanoff H**, McRee A, O'Neil B, Garmey E, Hennessy M, Eliasof S, Blackstock W, Tepper J, Wang AZ. A Phase Ib/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer. Clin Oncol 32:5s, 2014 (suppl; abstr TPS3667).
18. Quach C, **Sanoff H**, Williams G, Lyons J, Reeve BB. Impact of diagnosis and treatment of colorectal cancer on health-related quality of life among older americans. 2014 Academy Health Annual Research Meeting, Poster Session and Number: C, #1064.
19. Quach C, **Sanoff H**, Williams G, Lyons J, Reeve BB. Impact of colorectal cancer on activities of daily living and depression risk among older Americans. 2014 annual meeting of the International Society for Pharmacoeconomics and Outcomes Research, Poster Code PCN152.
20. Shaw AC, **Sanoff HK**, Smolkin ME. Effect of patient care of repeat pathologic review for breast cancer. J Clin Oncol 2013; 31 (suppl, abstr 6599). Also selected for oral presentation at the University of Virginia Carey-Marshall-Thorner Scholars and Research Day May 1, 2013.
21. El Sayed A, Dillon PM, Densmore J, Patrie J, **Sanoff HK**. Utility of the baseline cardiac imaging in the treatment decision for young patients with acute leukemia. J Clin Oncol 2013; 31 (suppl, abstr e18005).
22. Stitzenberg K, Penn D, **Sanoff H**, Meyers M. Surgical practice patterns and long-term survival for early-stage rectal cancer. Gastrointestinal Cancers Symposium 2013, abstract 459.
23. Chakraborty S, Bauer TW, Morris MM, Yarde E, Parsons JT, Adams RB, **Sanoff HK**. Accelerated fraction radiotherapy with concomitant capecitabine as neoadjuvant therapy of borderline resectable pancreatic cancer. J Clin Oncol 2012; 30 (suppl 4, abstract 329).
24. Lund JL, Sturmer T, Sandler RS, **Sanoff HK**, Harlan LC, Warren JL. Validation of specific chemotherapy drugs in Medicare data. J Clin Oncol 2011; 29 (suppl 4): abstract 6012.
25. Davies JM, McRee AJ, **Sanoff HK**, et al. Phase I study of the combination of everolimus with 5FU/LV in patients with refractory solid malignancies. J Clin Oncol 2011; 29 (suppl 4): abstract 512.
26. Mack CD, Carpenter WR, Meyer AM, **Sanoff H**, Sturmer T. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults. NCI Center to Reduce Cancer Health Disparities Program Meetings. Rockville MD, July 14, 2011.
27. Boyd JK, Jones DR, Kozower B, Lau C, **Sanoff HK**. The impact of diabetes mellitus and obesity on pathologic complete response rate of neoadjuvant chemoradiation for gastroesophageal cancer. A retrospective review. J Clin Oncol 2010; 28 (15S): (abstr e14627).
28. Davies JM, Raftery LL, **Sanoff HK**, et al. Phase I study of the combination of everolimus (RAD001) with panitumumab in patients with refractory solid malignancies. J Clin Oncol 2010; 28 (15S): abstr e13085.

**HANNA KELLY SANOFF, M.D.**  
**CURRICULUM VITAE**

29. Raftery LL, Tepper JE, Goldberg RM, Blackstock AW, Aklilu M, Bernard SA, **Sanoff HK**, Ivanova A, O'Neil BH. A phase I study of weekly oxaliplatin and gemcitabine during radiotherapy for unresectable pancreatic or biliary carcinoma. Proceedings of the GI Cancers Symposium 2010: abstract 220.
30. Liu Y, **Sanoff HK**, Torrice C, Petre CE, and Sharpless NE. Expression of  $p16^{INK4a}$  in peripheral blood T lymphocytes is a biomarker of human aging. Oral presentation. CSHL 2008 Meeting on Molecular Genetics of Aging (Sep 24-28, 2008), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory, New York.
31. **Sanoff HK**, Campbell ME, Pitot H, Goldberg RM, Sargent DJ. Risk Stratified Analysis Improves Prediction of Treatment (Rx) Benefit Over Subgroup Analysis: Findings from Intergroup N9741. J Clin Oncol 2008; 26 (abstr 4018). Poster Discussion.
32. O'Neil BH, Bernard SA, Goldberg RM, Moore DT, Garcia R, Marroquin C, Morse MA, Woods L, **Sanoff HK**. Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma. J Clin Oncol 2008; 26 (abstr 4604).
33. Shah U, **Sanoff HK**, O'Neil BH, Stinchcombe TE, Keller K, Carrizosa D, Walko CM, Buie L, Chiu W, Dees EC. A Phase I trial of vinflunine and pemetrexed. J Clin Oncol 2008; 26 (abstr 13508).
34. O'Neil BH, Bernard SA, Goldberg RM, Garcia R, Woods L, **Sanoff HK**. Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma. Proceedings of the GI Cancers Symposium 2008: 182 (abstr 228).
35. **Sanoff HK**, Sargent DJ, Campbell M, et al. N9741: Survival update and prognostic factor analysis of oxaliplatin and irinotecan combinations for metastatic colorectal cancer. J Clin Oncol 2007; 24 (18S) (abstr 4067).
36. **Sanoff HK** and Pignone MP. A systematic review of the use of quality of life measures in colorectal cancer research. Proceedings of the GI Cancers Symposium 2007: 248 (abstr 329).
37. **Sanoff HK** and Goldberg RM. Colorectal cancer treatment in older patients. Gastrointest Cancer Res 2007; 1(6): 248-253.
38. Collichio F, Ollila D, Huck K, Shearer H, Turner E, **Kelly H**, Zeger E, Socinski M, Hensing T. A phase II trial of weekly 1-hour paclitaxel in stage IV melanoma. J Clin Oncol 2005; 23 (S16): 726s (abstr 7565).
39. O'Neil BH, Farrah H, **Kelly H**, Baldwin AS, Funkhouser WK. Analysis of NF-kappa B in hepatocellular carcinoma reveal frequent activation of p50 and bcl-3. J Clin Oncol 2005; 23 (S16): 866s (abstr 9621).

Reviews (un-refereed)

1. Machado M, Harris T, **Sanoff HK**. Racial variations in colorectal cancer outcomes and the role of pharmacogenetics. Eur J Clin Med Oncol 2010, 2(3).
2. **Sanoff HK** and Goldberg RM. Searching for standards of care in gastroesophageal cancers. Oncology (Williston Park) 2007; 21(5): 591-592.
3. **Kelly H** and Goldberg RM. Can we cease to order CEAs yet? A commentary on "CEA monitoring in colorectal cancer: what you should know". Oncology (Williston Park) 2006; 20(6): 594-596.

**HANNA KELLY SANOFF, M.D.**  
**CURRICULUM VITAE**

4. **Kelly H** and Goldberg RM. Gefitinib: Probably not the best thing since sliced bread for colorectal cancer. *Am J Oncol Rev*, 2006; 5: 1-5.
5. **Kelly H** and Dees EC. The role of bisphosphonates in the management of breast cancer. *Am J Oncol Rev* 2005; 4: 248-251.
6. **Kelly H**, O'Neil BH, Goldberg RM. Optimizing adjuvant therapy of colon cancer—ongoing investigations. *Current Colorectal Cancer Reports* 2005; 1: 27-33.

Master's Thesis

**Sanoff HK.** Facing the rising cost of chemotherapy in an aging population: Proposed reform of the drug approval process, 2008 (59 pages).

Other products of scholarship

1. Clark JW and **Sanoff HK.** Adjuvant therapy for resected stage III (node-positive) colon cancer. In: *UpToDate*, version 90.0, updated April 2017.  
<http://www.uptodate.com/contents/adjuvant-therapy-for-resected-stage-iii-node-positive-colon-cancer>
2. **Sanoff HK.** Adjuvant chemotherapy for resected stage II colon cancer. In: *UpToDate*, version 69.0, updated April 2017.  
<http://www.uptodate.com/contents/adjuvant-chemotherapy-for-resected-stage-ii-colon-cancer>
3. **Sanoff HK.** Adjuvant therapy for resected colon cancer in elderly patients. In: *UpToDate*, version 37.0, updated January 2017.  
<http://www.uptodate.com/contents/adjuvant-therapy-for-resected-colon-cancer-in-elderly-patients>
4. **Sanoff HK.** Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status. In: *UpToDate*, version 45.0, updated January 2017.  
<http://www.uptodate.com/contents/therapy-for-metastatic-colorectal-cancer-in-elderly-patients-and-those-with-a-poor-performance-status>

Media

“Chemotherapy and aging: The treatment and the punishment.” *As It Happens*, Canadian Broadcasting Company, radio one. March 28, 2014. Radio interview.

**6) Teaching activities**

Lectures

*Invited Lectures—at UNC*

1. *Value Care Action Group Activity in the Division of Hematology/Oncology.* North Carolina Cancer Hospital Operations Meeting. March 22, 2017.
2. *Quality of Hepatocellular Carcinoma Care in North Carolina.* UNC Lineberger Cancer Outcomes Research Program Breakfast Seminar Series. February 14, 2017.
3. *GI Cancer for Internists.* UNC Internal Medicine Resident Didactic Conference. May 9, 2016.
4. *Research in GI Oncology at UNC.* UNC Hematology/Oncology Division Conference. September 14, 2015.

**HANNA KELLY SANOFF, M.D.**  
**CURRICULUM VITAE**

5. *Real-world (in)effectiveness of treatments for hepatocellular carcinoma.* UNC Lineberger Cancer Outcomes Research Program Breakfast Seminar Series. November 11, 2014.
6. *Current Treatment Paradigms for Pancreatic Cancer.* UNC TeleHealth Lecture Series. September 24, 2014. Available online <http://uncn.mediasite.mcn.org/mcnc/Play/03fedc5de7834c7eb0b7e12b6bff6ea21d?catalog=9934f851-def7-4082-9e63-defa937c3583>
7. *Tapping Epic for Intervention Research.* Panel Member, UNC LCCC Cancer Prevention and Control Quarterly Meeting. June 4, 2014.
8. *TACE or Theraspheres for Intermediate Stage HCC: Does it Matter?* GI Epidemiology Conference, March 26<sup>th</sup>, 2014.
9. *Colorectal Cancer.* Geriatric Oncology Retreat, Chapel Hill, NC. November 15, 2013.
10. *Integrating Health Services and Outcomes Research.* Panel Member, UNC Hematology/Oncology Faculty Retreat, Chapel Hill, NC. September 6, 2013.
11. *Colon Cancer.* UNC Internal Medicine Residents' Lecture, Chapel Hill, NC. June 11, 2013.
12. *Chemotherapy Induced Aging.* UNC Geriatric Oncology Working Group Lecture, Chapel Hill, NC. February 14, 2013.
13. *Comparative effectiveness in colon cancer research.* Health Policy and Management 886, Advanced Applications in Health Services Research Methods. Invited to co-teach a seminar with William Carpenter, PhD and Christopher Martin, MA. October 10, 2012. 2hr seminar.
14. *Gastrointestinal Cancers. Overview/Board Review,* UNC Internal Medicine Housestaff. May, 2007.
15. *The Dangers of Methotrexate in Renal Failure.* UNC OB/GYN Morbidity and Mortality Conference. March 8, 2006.

*Invited Lectures—outside UNC*

1. *NRG-GI004 COMMIT Trial Update.* Alliance GI Committee, Chicago, IL. November 4, 2016
2. *Adjuvant Chemotherapy for Stage III Colon Cancer.* Education session at the annual meeting of the American Society for Clinical Oncology. Chicago, IL. May 30<sup>th</sup>, 2015.
3. *Cancer Innovation in the Triangle (speaker and panelist).* Leadership Triangle Regional Leaders Program. Chapel Hill, NC. April 22, 2015.
4. *Systemic therapy strategies for managing elderly patients with colorectal cancer. Course 1008.* Biomedical Learning Institute CME Webcast on Cancer in the Elderly (Dr. Arti Hurria and Dr. Hyman Muss, co-chairs). December 17, 2014.
5. *Chemotherapy's Effect on Molecular Aging,* East Chapel Hill Rotary Club, Chapel Hill, NC. October 17, 2014
6. *GI Liaison Report.* Alliance Health Outcomes Committee, Chicago, IL. May 9, 2014.
7. *Rectal Cancer: Best Adjuvant Chemotherapy and its Future.* Novant Health, Perspectives in GI Cancer. Charleston, SC. February 7, 2014.

**HANNA KELLY SANOFF, M.D.**  
**CURRICULUM VITAE**

8. *Colon Cancer: Adjuvant Therapy in Stage II/III Disease*. Novant Health, Perspectives in GI Cancer. Charleston, SC. February 7, 2014.
9. *Update on Treatment Approaches for Colorectal Cancer*. North Carolina Oncology Association Fall Conference, Greensboro, NC. August 24, 2013.
10. *Academic Career Options*. Invited by the ASCO Career Development Subcommittee to a discussion with fellows and junior faculty regarding options in academic oncology at the annual meeting of the American Society of Clinical Oncology. June, 2012.
11. *Colon cancer: a primer for cancer scientists*. UVA Molecular Basis of Carcinogenesis course, Dept of Microbiology. Charlottesville, VA. January, 2012.
12. *Clinical Trials*. Advanced Topics in Cancer Seminar, UVA Department of Microbiology, November, 2011.
13. *Tumor invasion and metastasis*. for *Molecular & Cellular Medicine*, MS1 block, UVA School of Medicine. Co-taught with Drs. J.T. Parsons and A. Bouton. October, 2011.
14. *Comparative Effectiveness as a Cancer Research Tool*. The Dawn Hollins Memorial Lecture, UVA Department of Medicine, September, 2011.
15. *Clinical Cancer*. UVA Molecular Basis of Carcinogenesis course, Dept. of Microbiology. Charlottesville, VA. January, 2011.
16. *Clinical Trials*. Advanced Topics in Cancer Seminar, UVA Department of Microbiology, September, 2010.
17. *Breast and Colorectal cancer*. A clinician's practical approach". UVA Molecular Basis of Carcinogenesis course, Dept of Microbiology. Charlottesville, VA. January, 2010.
18. *Aging and Cancer*. Outer Banks Hospital Lunch and Learn Workshop. Nags Head, NC. March 20, 2009.
19. *Educating our guesses: refining chemotherapy decisions for older colorectal cancer patients*. Fox Chase Cancer Center, Philadelphia PA, December 3, 2008.
20. *Chemotherapy Update: Current therapy for colorectal cancer*. Area L, "Area Health Education Center", Nash General Hospital, Rocky Mount, NC. March 19, 2008.
21. *Treating older patients*. Leukemia and Lymphoma Society. Chapel Hill, NC February 7, 2008
22. *Lung, breast, laryngeal, and colorectal cancer case presentations*. Big Sky Oncology Update, Big Sky, Montana, August, 2004.

Grand Rounds—outside UNC

1. *What's New in Colorectal Cancer Treatment?* Grand Rounds, New Hanover Regional Medical Center, Wilmington, NC. May 21, 2014.
2. *Colorectal cancer at the start of a new decade*. UVA Department of Medicine Grand Rounds, Charlottesville, VA. May 18, 2010.

Research Mentorship

- Mentor for University of North Carolina Division of Hematology/Oncology fellow Emily Ray in cancer outcomes research, 2017- present

**HANNA KELLY SANOFF, M.D.**  
**CURRICULUM VITAE**

- Mentor for University of North Carolina Division of Hematology/Oncology junior faculty member Michael Lee, 2016- present
- Co-mentor for University of North Carolina Pharmaceutical Outcomes and Policy pre-doctoral student Ashley Cole. 2016- present
- Primary mentor for University of North Carolina Oncology Fellow Ranjit Jospeh in GI oncology clinical research; 2016 – present
- Primary mentor for University of North Carolina Oncology Fellow Tomohiro Nishijima in GI oncology clinical research; 2015 – present
- Mentor for University of North Carolina Internal Medicine Resident, Melissa Reimers, MD on a research project evaluating the prevalence of chemotherapy use at the end of life in solid tumor oncology patients. 2014-2016
- Primary mentor for University of North Carolina Oncology Fellow Grant Williams in GI oncology; co-mentor in research on geriatric oncology in patients with gastrointestinal cancer. 2013 – 2016
- Co-mentor for University of North Carolina junior faculty member Dr. Jennifer Lund, Department of Epidemiology. 2013- present
- Co-mentor for Dr. Enrique Soto Perez de Celis, Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Mexico. International Development and Education Award, American Society for Clinical Oncology. 2014
- Co-mentor for University of North Carolina MD candidate Jimmy Broughman in a MSTAR project studying prevalence and clinical relevance of sarcopenia in elderly colorectal cancer patients. 2013 – 2014
- Supervisor for the research practicum for Pradeep Poonnen, University of North Carolina MS III and MPH candidate. 2013
- Primary mentor for University of Virginia Internal Medicine Resident Andrew Shaw in clinical research design and conduct of ongoing project of the clinical utility of re-review of histopathology in patients present for consultation and/or care at the University of Virginia. 2011 – 2013
- Primary mentor for University of Virginia Hematology/Oncology Fellow Samhita Chakraborty in clinical trials design, conduct, and analysis. 2011 – 2013
- Co-mentor for University of Virginia Hematology/Oncology Fellow Ali El Sayed in clinical research design on a project evaluating the clinical utility of cardiac testing in patients under 50 years of age presenting with acute leukemia. 2011 – 2013
- Co-mentor for Christina Mack, candidate for doctorate in Pharmacoepidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill. Project entitled, *“Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer.”* 2011 – 2012

Graduate Supervision, Committees

**HANNA KELLY SANOFF, M.D.**  
**CURRICULUM VITAE**

- Dissertation committee member for Caroleen Quach, candidate for doctorate in Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill. Dissertation title: *“Joint Modeling of Health-Related Quality of Life Trajectories and Trial Efficacy Endpoints”*. 2016- present
- Dissertation committee member for Theresa Coles, candidate for doctorate in Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill. Dissertation title: *“The Association of Sleep Disturbance with Demographics, Clinical Factors, and Exercise in Adults with Colorectal Cancer”*. 2016- 2017
- Dissertation committee member for Peter Samai, candidate for doctorate in Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill. Dissertation title: *“Adult Changes in Weight and Physical Activity and Pancreatic Cancer Incidence in the VIT.A.L. Cohort”*. 2015-present
- Dissertation committee member for Caitlin Murphy, candidate for doctorate in Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill. Dissertation title: *“Colorectal Cancer in Young Adults”*. 2015-2016.
- Dissertation committee member for Jennifer Lund, candidate for doctorate in Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill. Dissertation title: *“An examination of the validity and patterns of chemotherapy use among colorectal cancer patients in administrative data.”* 2011 – 2012

Clinical Teaching

- Clinical and career mentor for UNC Hematology/Oncology Fellow Emily Ray, MD. 2016-2017
- Clinical and career mentor for UNC Hematology/Oncology Fellow Sarah Carroll, MD, 2015-2016
- Clinical and career mentor for UNC Hematology/Oncology Fellow Ashley Freeman, MD, 2014-2015
- Medical Oncology Director, UNC Surgical Oncology Fellowship Program, 2013 – present
- Key Faculty Member, UNC Hematology/Oncology Fellowship, 2013 – present
- Clinical Instruction, UNC Hematology/Oncology fellows in GI Medical Oncology Clinic Block, approximately 1-2 per 3 month block. 2013 – present
- Lecture to UNC Hematology/Oncology Fellows on GI cancers during the didactic portion of their training. Approximately 2 per year. 2013 – present
- Attending on Hematology/Oncology inpatient and consult services 4-6 weeks per year with teaching during daily rounds and scheduled didactic lectures 1-2 times per week. 2006 – present
- Lectures to UVA Hematology/Oncology Fellows on GI cancers during the didactic portion of their training. Approximately 4-6 per year. 2009 – 2012



**HANNA KELLY SANOFF, M.D.**  
**CURRICULUM VITAE**

- Instructor, UVA School of Medicine MS2 Oncology Case-Based Teaching. 2010 – 2011
- Director, UNC Hematology-Oncology Fellows Presentation Series, 2007 – 2008
- Course Director, UNC Hematology-Oncology Journal Club. 2006 – 2007
- Instructor, UNC Breast Cancer Clinical Case Days, MS1 curriculum. 2005 – 2007
- Lab Instructor, UNC Hematology Case Based Laboratory, MS2 curriculum. 2005 – 2007
- Tutor, UNC Hematology/Oncology MS2 curriculum, 2004 – 2007

Clinical Supervision

- Aimee Faso, Clinical Pharmacist in GI Medical Oncology, 2014 – present
- Tammy Triglianios, Nurse Practitioner in GI Medical Oncology, 2013 – present
- Joan Van Ord, Clinical Nurse Specialist in GI Medical Oncology, 2013- 2017

**7) Grants**

Active

MCC 17651	(Sanoff)	6/1/15	6/1/18	0.00	Calendar (0.00%)
					H. Lee Moffitt Cancer Center and Research Institute
					328,511.00

**Multi Institutional Phase II Trial of Single Agent Regorafenib in Refractory Advanced Biliary Cancers**

Primary Objective is to determine the 6 month overall survival in patients with advanced refractory BC receiving regorafenib.

MK3475-059	(Sanoff)	6/1/15	5/31/18	0.60	Calendar (5.00%)
					Merck & Co.
					384,389.00

**A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma**

To determine the safety and tolerability of pembrolizumab administered at 200 mg Q3W dosing as monotherapy and in combination with cisplatin and 5-fluorouracil in subjects with recurrent and/or metastatic gastric or gastroesophageal junction adenocarcinoma.

550KR131607	(Dusetzina PI)	1/1/2017	12/31/17	0	calendar (0%)
-------------	----------------	----------	----------	---	---------------

**NC TraCS Pilot Award**

“Less is More? Evaluating Surveillance Patterns after Non-Operative Management Compared to Conventional Management for Older Individuals with Rectal Cancer”. This award provides funds our team to evaluate trends in and characteristics associated with use of non-operative management for rectal cancer patients in SEER Medicare. We will also be evaluating post-treatment surveillance / screening patterns in patients with NOM. Dr. Sanoff’s role will be that of a co-investigator.

PB-1201	(Sanoff)	12/22/14	12/31/17	0.60	Calendar (5.00%)
					Precision Biosciences
					111,300.00

HANNA KELLY SANOFF, M.D.

CURRICULUM VITAE

**A Multicenter Randomized Phase II Study of NPC-1C in Combination with Gemcitabine and nab-Paclitaxel versus Gemcitabine and nab-Paclitaxel alone in Patients with Metastatic or Locally Advanced Pancreatic Cancer Previously Treated with FOLFIRINOX**

To determine the safety and tolerability of NPC-1C (NEO-102) monoclonal antibody therapy in combination with Gemcitabine as a second line therapy in subjects with metastatic locally advanced unresectable or recurrent pancreatic cancer previously treated with FOLFIRINOX and whose tumors bind NPC-1C by at least 20% on IHC.

5-K12CA120780-09 (Sharpless, PI) 7/1/2006 8/31/2017 1.8 Calendar (15%)  
National Cancer Institute

**UNC Oncology Clinical Translational Research Training Program**

The program's objectives are to establish a highly motivated and rigorously trained cadre of physician clinical researchers who are competitive in seeking research support and who will become successful, independent patient-oriented cancer investigators. Dr. Sanoff's role is that of Program Director.

Pending

K23 Williams (PI) 07/01/17-06/30/22

**National Cancer Institute**

Sarcopenia Trajectories and Pharmacokinetics in Older Adults with Colorectal Cancer: The STP Study

The central goal of our prospective study is to better understand sarcopenia and its association with chemotoxicity and other adverse outcomes in older adults with metastatic CRC. The study examines sarcopenia to understand inter-individual variability in chemotoxicity in older adults and evaluates the role of altered pharmacokinetics in sarcopenic patients to explain increased rates of chemotoxicity. Role: Mentor

NA Lund (PI) 1/1/18-12/31/20

**National Cancer Institute (R01)**

A Hybrid Approach to Estimating the Effectiveness of Cancer Therapies

We propose to use individual-level patient data from: (1) two phase III trials of adjuvant chemotherapy in breast and colon cancer and (2) cohorts of similar patients treated within a large network of community oncology practices, and employ state-of-the-art statistical methods to estimate the effectiveness of adjuvant chemotherapy on mortality and adverse events. Our research will catalyze the broader application of these methods to trials of other cancer sites and therapy modalities that will enhance knowledge of the effectiveness of standard cancer therapies in routine care settings. Role: Co-Investigator

Completed

LCCC 1029 (Sanoff) 12/6/2010 12/31/2016 0.60 Calendar (5.00%)  
Bayer 1,518,757.00

**Randomized Phase II Study of Regorafenib in Combination with FOLFIRI (Irinotecan, r-Fluoracil, and Leucovorin) versus Placebo in Combination with FOLFIRI as Second Line Therapy in Patients with KRAS or BRAF Mutant Metastatic Colorectal Cancer**

This is a randomized Phase II Study of Regorafenib in combination with FOLFIRI (Irinotecan, r-Fluoracil, and Leucovorin) versus placebo in combination with FOLFIRI as second line therapy in patients with KRAS or BRAF mutant metastatic colorectal cancer. Dr. Sanoff's role is that of PI.

7-K07-CA160722-05 (Sanoff) 9/1/2012 8/31/2016 9.00 Calendar (75.00%)

**HANNA KELLY SANOFF, M.D.**  
**CURRICULUM VITAE**

National Cancer Institute 850,500  
**Use and Comparative Effectiveness of Innovative Therapies for Hepatocellular Carcinoma**

The proposed research forms the core of a five year training program in CE research and HCC. Highlights of the training program include didactic training in the methods needed to analyze large observational datasets, health services research content, and multidisciplinary HCC training. Dr. Sanoff's role was that of PI.

ME-1303-5838 (Reeves/McCormack) 12/1/2013 11/30/2016 0.90 Calendar (7.50%)  
Patient-Centered Outcomes Research Institute 89,325.00

**Measuring Patient-Centered Communication for Colorectal Cancer Care and Research – Subcontract with Research Triangle Institute (RTI International)**

In this proposal our organization will be supporting the RTI International team by providing clinical and psychometric expertise as well as the services of UNC's Rapid Case Ascertainment (RCA) core facility. Dr. Sanoff's role was that of co-investigator.

550KR61327 (Lund, Sanoff co-PIs) 6/1/2014 5/31/2015 0 calendar (0%)  
**NC TraCS Pilot Award** 0

"Improved measurement of patient frailty and comorbidity for targeting subgroups of older adults in cancer comparative effectiveness research." This award provides funds for methodologic research on ways to improve controlling for confounding in observational research in the elderly.

**2014 Junior Faculty Development Award** (Sanoff) 1/1/2014 12/31/2014 0 calendar (0%)  
University of North Carolina at Chapel Hill

The purpose of this project is to provide preliminary evidence on the lasting effect of chemotherapy on the physical function, energy, and quality of life of elderly colorectal cancer survivors. These data will support an application for a trial designed to test whether exercise can mitigate the long-term pro-aging effects of chemotherapy on cancer survivors.

1KL2RR025746-01 (Pisano) 5/19/2008 4/30/2013 (75%)  
NIH/NCRR 2,090,864 (Direct)

**UNC Clinical Translational Science Award-K12 Scholars Program (KL2).**

A national consortium with the goal of transforming how clinical and translational research is conducted, ultimately enabling researchers to provide new treatments more efficiently and quickly to patients. Dr. Sanoff's role in the grant was that of funded Scholar from 5/2008-6/2009.

Pilot award 4/2010 5/2012 (0 %)  
UVA Cancer Center Commonwealth Fund for Cancer Research 28,000

**Translational Phase II study of accelerated fraction radiotherapy and concurrent capecitabine as neoadjuvant therapy for localized pancreas cancer with molecular determinants of resistance.**

This award provides funds for a pilot study of a novel radiation platform and a molecular assessment of mechanisms of treatment resistance in orthotopic xenograft models of pancreatic cancer. Dr. Sanoff's role is that of principal investigator.

Clinical Scientist Award in Translational Research (Sharpless) 7/2007 3/2012 (5%)  
Burroughs Wellcome Foundation

**p16INK4a Tumor Suppressor in Stem Cell Aging**



**HANNA KELLY SANOFF, M.D.**  
**CURRICULUM VITAE**

- American Society of Clinical Oncology, 2004 – present
- Eastern Cooperative Oncology Group, 2009 – 2012

*State and National*

- Annual Meeting Scientific Program Committee, Gastrointestinal (Colorectal) Cancer. American Society of Clinical Oncology. 2017
- Special Government Employee to the FDA Oncology Drugs Advisory Committee. 2016- present
- Data Safety Monitoring Board Member, Big 10 Cancer Research Consortium BTCRC-ESO14-012 Trial, 2016- present
- Alliance for Clinical Trials in Oncology Co-Chair, NRG-GI004/SWOG-S1610 (COMMIT) study (PI, James Lee, University of Pittsburgh), 2016- present
- Member, ASCO University Question Writing Group, 2016- present
- Member, ASCO Educational Book Expert Panel. 2016, 2017
- Member, GI Committee, Alliance Cancer Control Program. 2016- present
- Expert Panel Member, *FDA Mini-symposium on Colorectal Cancer*. FDA White Oak Campus, Silver Spring, MD. June 2015.
- Member, Alliance-ACS Cancer Care Delivery Research Committee. 2014-
- Member, Hoosier Cancer Research Network, GI Clinical Trials Working Group, 2014 – present
- Liaison to the GI Committee, Health Outcomes Committee, Alliance Cancer Control Program. 2014 – present
- Member, Health Outcomes Committee, Alliance Cancer Control Program. 2013 – present
- Junior member for ECOG, NCI's Steering Committee Anal-Rectal Task Force. 2010

*Advisory and Editorial Appointments*

- Member advisory group for NCI R21 application for East Carolina Faculty members Suzanne Lea, PhD and Kyle Mansfield, PhD on C-terminal binding protein expression in colorectal cancer. 2014
- Faculty of 1000 Medicine, Associate Oncology Faculty Member, Cancer in the Elderly Section (Section heads: Matti Aapro, Harvey Cohen, Silvio Monfardini). 2009 – 2011
- Ad Hoc Peer Review: American Journal of Clinical Oncology; American Journal of Managed Care; Annals of Oncology; Cancer; Cancer Chemotherapy and Pharmacology; Cancer Epidemiology, Biomarkers & Prevention; Cancer Investigation; Clinical Colorectal Cancer; Cochrane Database of Systematic Reviews; Critical Reviews in Oncology/Hematology; Expert Opinion on Biological Therapy; JAMA; JAMA Oncology; Journal of Clinical Gastroenterology; Journal of Clinical Oncology; Journal of Geriatric Oncology; Medical Decision Making; Oncology; Pharmacogenomics; PLOS ONE; The Oncologist.

**HANNA KELLY SANOFF, M.D.**  
**CURRICULUM VITAE**

*Expert Clinical Review*

- Member *Best Doctors* expert review panel. 2016- present

Service to UNC-CH

*Committees*

- UND Department of Medicine Patient and Family Centered Care Committee, 2017-
- UNC Department of Medicine Value Care Action Group, 2016- present
- UNC Hematology/Oncology Executive Committee Member, 2013 – present
- UNC Institutional Review Board Biomedical Committee Member, 2015-
- LCCC Clinical Protocol Office POD leader for GI Oncology, 2013-2016
- LCCC Protocol Office Executive Committee Member, 2013 – 2016
- LCCC Protocol Review Committee, 2013 – 2015
- UNC GI Medical Oncology Faculty Search Committee Member, 2013 – 2015
- LCCC GI Spore Application Planning Committee (Chair: Tepper), 2013 – 2014
- UNC EPIC Research Extended Core Team, representing LCCC, 2013-2014
- UNC EPIC Subject Matter Expert, BEACON Oncology development team, 2013-2014
- Member, UNC Lineberger Comprehensive Cancer Center, Cancer Prevention and Control and Clinical Research Programs, Chapel Hill, NC 9/2012 – present
- UNC Hematology-Oncology Fellows clinic restructuring working group, 2006
- UNC Inpatient Oncology Restructuring Committee, 2004

*Grant Review*

- Reviewer, LCCC Developmental Awards in Population Sciences Cancer Research, 2013

Other

*Professional Development*

- AAMC Mid-Career Women Faculty Professional Development Course, Austin TX, December 10-13, 2016.
- ASCO Item Writing Workshop, Alexandria, VA, September 8, 2016.